
# J.P.Morgan

### How much BBB debt will fall to HY?

We look to history, market pricing and our analysts for answers

- BBB-rated Non-Financial bonds have grown to \$2.3tr outstanding, from \$883bn in 2011, a 164% increase over 7 years
- The BBB market is now 4.8x larger than the BB market. It was 2.9x larger 10 years ago
- If there is a significant amount of rating migration from HG to HY, it will have a meaningful impact on both HG and HY bond markets
- In this note, we discuss downgrade risk from three perspectives: what history tells us, what the market is pricing, and the JPM sector analysts' views
- In 2017 and 2018 just \$11bn and \$18bn of Non-Financial index debt went from HG to HY. This represents 0.3% and 0.5% of the HG Non-Financial market, respectively, well below the historical average of 2.7% per year
- Using historical downgrade rates by rating bucket and applying these to the current market size and rating profile results in \$108bn/year of 'expected' HG to HY downgrades
- Market pricing suggests that \$137bn of BBB debt (5.8%) is priced for downgrade to BB
- Our analysts believe that downgrade risk is lower than these figures. For many of the largest 50 BBB issuers we believe the risk of downgrade to BB is overpriced
- While many large HG bond issuers chose to go from an A to BBB rating through M&A and a shareholder focus in recent years, we believe most have both the interest and ability to avoid a HY rating going forward
- We introduce a forecast of fallen angels of \$40bn in 2019 and \$60bn in 2020. \$17bn PCG debt has already been downgraded this year

#### Our forecast is that \$40bn will fall from HG to HY in 2019 and \$60bn in 2020



Source: J.P. Morgan

#### **US High Grade Strategy & Credit Derivatives Research**

#### Eric Beinstein AC

(1-212) 834-4211 eric.beinstein@jpmorgan.com

#### Matthew Anavy, CFA

(1-212) 834-3568

matthew.a.anavy@jpmorgan.com

#### Claire Barbour

(1-212) 270-6861

claire.barbour@jpmchase.com

#### Virginia Chambless, CFA

(1-212) 834-5481

virginia.chambless@jpmorgan.com

#### Brett G. Gibson

(1-212) 270-7484

brett.g.gibson@jpmorgan.com

#### **Paul Glezer**

(1-212) 270-8185

paul.x.glezer@jpmorgan.com

#### Jonathan Rau, CFA

(1-212) 834-5237

jonathan.d.rau@jpmorgan.com

#### Mark Streeter, CFA

(1-212) 834-5086

mark.streeter@jpmorgan.com

#### Pavan D Talreja

(1-212) 834-2051

pavan.talreja@jpmchase.com

#### **Dominique Toublan**

(1-212) 834-2370

dominique.d.toublan@jpmorgan.com

#### **Brian Turner**

(1-212) 834-4035

brian.m.turner@jpmorgan.com

#### Sheila Xie

(1-212) 834-3036

sheila.xie@jpmorgan.com J.P. Morgan Securities LLC

#### See page 25 for analyst certification and important disclosures.

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

### **Table of Contents**

The BBB market has grown rapidly, more so than the BB market	4
The drivers of rating deterioration within High Grade credit include low borrowing osts and significant M&A	_
Downgrades from HG to HY over the past two years been the lowest two years single 2000	nce 6
Approach 1: The historical downgrade pattern predicts about \$108bn/4.6% of BBI lebt could fall to HY each year	
Approach 2: Market pricing suggests \$137bn/5.8% of BBB debt is priced in the ange of BB debt	9
Approach 3: Our analysts believe the risk of downgrade to HY for the largest issues below that implied by either the historical approach or the market-based approach.	ch
Our forecast is that \$40bn will fall from HG to HY in 2019, \$60bn in 2020	11
A sector by sector review of the top 50 BBB credits	12
Other credits not in the top 50 BBB issuer list with significant fallen angel risk	23

#### The 50 largest BBB rated non-Financial bond issuers

The table below, sorted from most to least amount of index debt, shows each issuer's current rating profile, the amount of index debt, the probability of downgrade over the next 2 and 3 years assuming the historical downgrade rates prevail, and the probability of downgrade to HY implied by bond spreads. The methodology for these calculations is described in this note.

AT&T Inc Anheuser-Busch Cos LLC Verizon Communications Inc CVS Health Corp GE Capital International Funding Co General Motors Financial Co Inc Charter Communications Operating United Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc Amgen Inc Chemical Co Enterprise Products Operating Williams Cos Inc/The Bayer US Finance II LLC Celgene Corp Minder Morgan Ele Bayer US Finance II LC Celgene Corp Coll International LLC / EMC Union Pacific Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications Mealti	sector  elecoms onsumer elecoms th & Pharma ap Goods atomotive ledia Ent ap Goods th & Pharma atomotive th & Pharma atomotive th & Pharma tenergy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy ledia Ent Energy th & Pharma	Bond spread  117 95 77 118 179 198 193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Moody's/ S&P/ Fitch  Baa2/BBB/A- Baa1/A-/BBB Baa1/BBB+/A- Baa2/BBB/- Baa1/BBB+/BBB- Baa1/BBB-BBB-Baa1/BBB-WD Baa2/A-/- Baa3/BBB/BBB-Baa2/A-/- Baa3/BBB-BBB-Baa2/BBB-BBB-Baa1/ABBB-BBB-Baa1/ABBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-Baa1/BBB-BBB-BBB-BBB-BBB-BBB-BBB-BBB-BBB-BB	Index	Debt (\$bn) 95 80 72 66 46 41 38 34 33 33 30 29 28 25 24 23 22	2Y avg 5% 3% 5% 5% 5% 24% 5% 5% 5% 5% 4% 5% 5% 4% 18%	3Y avg 8% 5% 8% 5% 8% 8% 8% 8% 8% 8% 6% 6% 26%	2Y avg+ 1std dev  10% 7% 10% 7% 10% 38% 8% 10% 10% 10% 10% 58% 10% 59%	3Y avg+ 1std dev  14% 10% 10% 14% 10% 14% 49% 11% 14% 14% 14% 14% 14% 14% 14% 14% 14	downgrade probability  <15% <15% <15% <15% <15% <15% <55% <55
Anheuser-Busch Cos LLC Verizon Communications Inc CVS Health Corp GE Capital International Funding Co General Motors Financial Co Inc Charter Communications Operating United Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc Amgen Inc Centerprise Products Operating Williams Cos Inc/The Bayer US Finance II LLC Celgene Corp Shire Acquisitions Investments Anthem Inc Albott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications Melatit Discovery Communications Melatit CVS Health Coc Comp Coc	onsumer felecoms th & Pharma ap Goods attomotive ledia Ent ap Goods th & Pharma attomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy ledia Ent Energy th & Pharma	117 95 77 118 179 198 193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa1/A-/BBB Baa1/BBB+/A- Baa2/BBB/- Baa1/BBB+/BBB+ Baa1/BBB-/BBB- Baa1/BBB+/WD Baa2/A-/- Baa3/BBB/BBB Baa2/A-/BBB- Baa2/BBB+/BBB- Baa2/BBB/BB- Baa1/A/BBB- Baa1/A/BBB- Baa1/A/BBB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BBB- Baa3/BBB/BB- Baa3/BBB/BB-	BBB+ BBB+ BBB+ BBB- BBB- BBB- BBB- BBB-	95 80 72 66 46 41 38 34 33 33 33 30 29 28 25 24 23 22	5% 3% 3% 5% 3% 5% 24% 3% 5% 5% 5% 5% 5% 5% 44% 18%	8% 5% 5% 8% 5% 8% 34% 5% 8% 8% 34% 8% 8% 5% 6%	10% 7% 7% 10% 7% 10% 38% 8% 10% 10% 38% 10% 10% 9%	14% 10% 10% 14% 10% 14% 49% 11% 14% 14% 14% 14% 14% 14% 10%	<15% <15% <15% <15% <15% <45-60% 30-45% <15% <15% <15% <15% <15% <15% <15% <1
Anheuser-Busch Cos LLC Verizon Communications Inc CVS Health Corp GE Capital International Funding Co General Motors Financial Co Inc Charter Communications Operating United Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc Amgen Inc Centerprise Products Operating Williams Cos Inc/The Bayer US Finance II LLC Celgene Corp Shire Acquisitions Investments Anthem Inc Albott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications Melatit Discovery Communications Melatit CVS Health Coc Comp Coc	onsumer felecoms th & Pharma ap Goods attomotive ledia Ent ap Goods th & Pharma attomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy ledia Ent Energy th & Pharma	95 77 118 179 198 193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa1/A-/BBB Baa1/BBB+/A- Baa2/BBB/- Baa1/BBB+/BBB+ Baa1/BBB-/BBB- Baa1/BBB+/WD Baa2/A-/- Baa3/BBB/BBB Baa2/A-/BBB- Baa2/BBB+/BBB- Baa2/BBB/BB- Baa1/A/BBB- Baa1/A/BBB- Baa1/A/BBB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BBB- Baa3/BBB/BB- Baa3/BBB/BB-	BBB+ BBB+ BBB+ BBB- BBB- BBB- BBB- BBB-	80 72 66 46 41 38 34 33 33 30 29 28 25 24 23 22	3% 3% 5% 3% 5% 24% 3% 5% 5% 5% 5% 5% 4% 18%	5% 5% 8% 5% 8% 34% 5% 8% 8% 8% 8% 5% 6%	7% 7% 10% 7% 10% 38% 8% 10% 10% 38% 10% 10% 9%	10% 10% 14% 10% 14% 49% 11% 14% 14% 14% 49% 14% 14% 10%	<15% <15% <15% <15% 45-60% 30-45% <15% <15% <15% <15% <15% <15% <15% <1
Verizon Communications Inc CVS Health Corp GE Capital International Funding Co General Motors Financial Co Inc Charter Communications Operating Milited Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc Amgen Inc Extra Communications MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Williams Cos Inc/The Bayer US Finance II LLC Celgene Corp Union Pacific Corp Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enterprise Inc Corp Corp Corp Corp Corp Corp Corp Corp	telecoms th & Pharma ap Goods utomotive ledia Ent ap Goods the A Pharma utomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy the A Pharma	77 118 179 198 193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa1/BBB+/A-Baa2/BBB/BB+Baa3/BBB/BBB+/BBB-Baa1/BBB+WDBBB-Baa2/A-/BBB-Baa2/A-/BBB-Baa2/BBB-BBB-Baa1/A/BBB-Baa1/A/BBB-Baa3/BBB/BBB-Baa3/BBB/BB-Baa3/BBB/BB-Baa3/BBB/BB-Baa3/BBB/BB-Baa3/BBB/BBB-Baa3/BBB/BBB-Baa1/BBB+BBB-Baa1/BBB+BBB-Baa1/BBB+BBB-Baa1/BBB+BBB-Baa1/BBB+BBB-Baa1/BBB+BBB-Baa1/BBB+BBB-Baa1/BBB+BBB-BBB-BBB-BBB-BBB-BBB-BBB-BBB-BBB	BBB+ BBB BBB+ BBB- BBB+ BBB BBB- BBB- B	72 66 46 41 38 34 33 33 30 29 28 25 24 23 22	3% 5% 3% 5% 24% 3% 5% 5% 5% 5% 5% 5% 4% 18%	5% 8% 5% 8% 34% 5% 8% 8% 34% 8% 5% 6%	7% 10% 7% 10% 38% 8% 10% 10% 10% 38% 10% 9%	10% 14% 10% 14% 49% 11% 14% 14% 14% 14% 49% 14% 14% 10%	<15% <15% <15% <560% 30-45% <15% <15% <15% <15% <15% <15% <15% <1
CVS Health Corp GE Capital International Funding Co General Motors Financial Co Inc Charter Communications Operating United Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc Dow Chemical Co Basic MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Williams Cos Inc/The Bayer US Finance II LLC Celgene Corp Dell International LLC / EMC Union Pacific Corp Vodafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Tre CSX Corp Tre Enbridge Inc Discovery Communications Mealting Authorited McDonald's Corp Tre CSX Corp Tre CSX Corp Tre Enbridge Inc Discovery Communications Mealting Authorited McDonalcy Communications McDonalcy Corp Tre CSX Corp Tre Enbridge Inc Discovery Communications McDonalcy Commu	ap Goods utomotive ledia Ent ap Goods th & Pharma utomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma	118 179 198 193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa2/BBB/- Baa1/BBB+/BBB- Baa1/BBB+/WD Baa2/A-/- Baa3/BBB/BBB Baa2/A-/BBB- Baa2/A-/BBB- Baa2/A-/BBB- Baa2/BBB+/BBB- Baa2/BBB+/BBB Baa2/BBB/NR Baa3/BBB/BB- Baa3/BBB/BB- Baa1/BBB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa1/BBB+/BBB- Baa1/BBB+/BBB- Baa2/BBB/-	BBB BBB+ BBB- BBB- BBB- BBB- BBB- BBB-	66 46 41 38 34 33 33 30 29 28 25 24 23 22	5% 3% 5% 24% 5% 5% 5% 24% 5% 5% 4% 18%	8% 5% 8% 34% 5% 8% 8% 34% 8% 5% 6%	10% 7% 10% 38% 8% 10% 10% 10% 38% 10% 7% 9%	14% 10% 14% 49% 11% 14% 14% 49% 14% 14% 10%	<15% <15% 45-60% 30-45% <15% <15% <15% <15% <15% <15% <15% <1
GE Capital International Funding Co General Motors Financial Co Inc Charter Communications Operating United Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Energy Transfer Operating LP BAT Capital Corp EMINDER INC EMIND	ap Goods utomotive ledia Ent ap Goods th & Pharma utomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma	179 198 193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa1/BBB+/BBB+ Baa3/BBB/BBB- Baa1/BBB+/WD Baa2/A-/- Baa3/BBB/BBB- Baa2/A-/BBB- Baa2/A-/BBB- Baa2/BBB+/BBB- Baa2/BBB/BBB- Baa2/BBB/BB- Baa1/A/BBB- Baa2/BBB/NR Baa3/BBB/BB- Baa3/BBB/BB- Baa1/BBB+/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB+ BBB BBB+ BBB BBB BBB- BBB- BBB- BB	46 41 38 34 33 33 30 29 28 25 24 23 22	3% 5% 24% 3% 5% 5% 5% 5% 24% 5% 5% 3% 4%	5% 8% 34% 5% 8% 8% 34% 8% 5% 6%	7% 10% 38% 8% 10% 10% 10% 10% 7% 9%	10% 14% 49% 11% 14% 14% 14% 14% 49% 14% 14% 10%	<15% 45-60% 30-45% <15% <15% >90% <15% <15% <15% <15% <15% <15% <15% <15
General Motors Financial Co Inc Charter Communications Operating United Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc BOW Chemical Co Basic MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Williams Cos Inc/The Bayer US Finance II LLC Celgene Corp Dell International LLC / EMC Union Pacific Corp Vodafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications M	utomotive ledia Ent ap Goods th & Pharma utomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma	198 193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa3/BBB/BBB Ba1/BBB+/WD Baa2/A-/- Baa3/BBB/BBB Baa2/A-/BBB- Baa2/A-/BBB- Baa2/BBB+/BBB Baa2/BBB/BBB- Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BB- Baa3/BBB/BB- Baa1/BBB+/BBB- Baa1/BBB+/BBB-	BBB BBB- BBB- BBB BBB- BBB- BBB- BBB-	41 38 34 33 33 33 30 29 28 25 24 23 22	5% 24% 3% 5% 5% 5% 24% 5% 5% 3% 4% 18%	8% 34% 5% 8% 8% 34% 8% 5% 6%	10% 38% 8% 10% 10% 10% 38% 10% 7% 9%	14% 49% 11% 14% 14% 49% 14% 14% 10%	45-60% 30-45% <15% <15% >90% <155% <15% <15% <15% <15% <15% <15%
Charter Communications Operating United Technologies Corp Ca AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Healti Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc BAT Capital Co MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp MWilliams Cos Inc/The Bayer US Finance II LLC Celgene Corp Dell International LLC / EMC Union Pacific Corp Wodafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Tre CDiscovery Communications Minimal Male and The Aller and The All	ledia Ent ap Goods th & Pharma utomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy the Energy	193 90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Ba1/BBB-/BBB- Baa1/BBB+/WD Baa2/A-/- Baa3/BBB/BBB Baa2/A-/BBB- Baa2/BBB-/BBB- Baa2/BBB-/BBB- Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BB- Baa3/BBB/BB- Baa1/BBB-BB- Baa1/BBB-BB-Baa1/BBB-BB-Baa1/BBB-BB-BB-BB-BB-BB-BB-BB-BB-BB-BB-BB-BB	BBB- BBB+ BBB BBB BBB- BBB- BBB+ BBB- BBB- BBB- BBB- BBB-	38 34 33 33 33 30 29 28 25 24 23 22	24% 3% 5% 5% 5% 24% 5% 5% 3% 4%	34% 5% 8% 8% 34% 8% 8% 5% 6%	38% 8% 10% 10% 10% 38% 10% 7% 9%	49% 11% 14% 14% 49% 14% 14% 10%	30-45% <15% <15% >90% <15% <15% <15% <15% <15% <15%
United Technologies Corp AbbVie Inc Ford Motor Credit Co LLC Cigna Corp Energy Transfer Operating LP BAT Capital Corp Amgen Inc Energy Inc Ener	ap Goods th & Pharma utomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy ensumer Energy the dia Ent Energy the & Pharma the & Pharma	90 118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa1/BBB+/WD Baa2/A-/- Baa3/BBB/BBB Baa2/A-/BBB- Baa3/BBB-/BBB- Baa2/BBB+/BBB Baa2/BBB/BB- Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BB- Baa3/BBB/BB- Baa1/BBB+/BBB- Baa1/BBB+/BBB- Baa1/BBB+/BBB-	BBB+ BBB BBB BBB- BBB- BBB+ BBB- BBB- B	33 33 33 30 29 28 25 24 23 22	3% 5% 5% 5% 24% 5% 5% 3% 4% 18%	5% 8% 8% 84% 34% 8% 5% 6%	8% 10% 10% 10% 38% 10% 7% 9%	11% 14% 14% 14% 49% 14% 14%	<15% <15% >90% <15% <15% <15% <15%
AbbVie Inc Healti Ford Motor Credit Co LLC Au Cigna Corp Healti Energy Transfer Operating LP Energy En	th & Pharma utomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy tedia Ent Energy th & Pharma th & Pharma	118 294 113 158 155 123 87 105 139 128 92 99 130 146	Baa2/A-/- Baa3/BBB/BBB Baa2/A-/BBB- Baa3/BBB-/BBB- Baa2/BBB/BBB- Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BB- Baa3/BBB/BB- Baa3/BBB/BB- Baa1/BBB+/BBB- Baa1/BBB+/BBB-	BBB BBB BBB- BBB- BBB- BBB+ BBB- BBB- B	33 33 33 30 29 28 25 24 23 22	5% 5% 5% 24% 5% 5% 3% 4% 18%	8% 8% 84% 34% 8% 5% 6%	10% 10% 10% 38% 10% 10% 7% 9%	14% 14% 14% 49% 14% 14%	<15% >90% <15% <15% <15% <15% <15%
Ford Motor Credit Co LLC  Cigna Corp  Healti Energy Transfer Operating LP  BAT Capital Corp  Kinder Morgan Inc  Amgen Inc  Amgen Inc  MPLX LP  Kraft Heinz Foods Co  Enterprise Products Operating  Fox Corp  Milliams Cos Inc/The  Bayer US Finance II LLC  Celgene Corp  Healti  Dell International LLC / EMC  Union Pacific Corp  Shire Acquisitions Investments  Anthem Inc  Abbott Laboratories  Allergan Funding SCS  Enel Finance International NV  Southern Co/The  CSX Corp  Ti  CSX	atomotive th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	294 113 158 155 123 87 105 139 128 92 99 130 146	Baa3/BBB/BBB Baa2/A-/BBB- Baa3/BBB-/BBB- Baa2/BBB/BBB- Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BBB- Baa3/BBB/BBB- Baa3/BBB/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB BBB BBB- BBB BBB+ BBB- BBB- BBB- BB	33 33 30 29 28 25 24 23 22	5% 5% 24% 5% 5% 3% 4% 18%	8% 8% 34% 8% 8% 5% 6%	10% 10% 38% 10% 10% 7% 9%	14% 14% 49% 14% 14% 10%	>90% <15% <15% <15% <15% <15%
Cigna Corp Healti Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc Healti Dow Chemical Co Basic MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Milliams Cos Inc/The Bayer US Finance II LLC Healti Union Pacific Corp Dell International LLC / EMC Union Pacific Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications Mealti	th & Pharma Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	158 155 123 87 105 139 128 92 99 130 146	Baa2/A-/BBB- Baa3/BBB-/BBB- Baa2/BBB/BBB- Baa1/A/BBB- Baa1/A/BBB- Baa3/BBB/NR Baa3/BBB/BBB- Baa3/BBB/BBB- Baa3/BBB/BBB- Baa1/BBB+/BBB+	BBB- BBB BBB+ BBB- BBB- BBB- BBB- BBB+	33 30 29 28 25 24 23 22	5% 24% 5% 5% 3% 4% 18%	8% 34% 8% 8% 5% 6%	38% 10% 10% 7% 9%	14% 49% 14% 14% 10%	<15% <15% <15% <15%
Energy Transfer Operating LP BAT Capital Corp Kinder Morgan Inc Amgen Inc Amgen Inc Healti Dow Chemical Co Basic MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Milliams Cos Inc/The Bayer US Finance II LLC Celgene Corp Healti Union Pacific Corp Union Pacific Corp MCDonald's Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Tre CDiscovery Communications Mealti	Energy onsumer Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	158 155 123 87 105 139 128 92 99 130 146	Baa3/BBB-/BBB-Baa2/BBB/BBB-Baa1/A/BBBB-Baa2/BBB/NRBaa3/BBB/BBB-Baa3/BBB/BBB-Baa1/BBB+/BBB+Baa2/BBB/-Baa2/BBB/-Baa2/BBB/-	BBB- BBB BBB+ BBB- BBB- BBB- BBB- BBB+	30 29 28 25 24 23 22	24% 5% 5% 3% 4% 18%	34% 8% 8% 5% 6%	38% 10% 10% 7% 9%	49% 14% 14% 10%	<15% <15% <15% <15%
BAT Capital Corp Co Kinder Morgan Inc Healti Dow Chemical Co Basic MPLX LP E Kraft Heinz Foods Co Co Enterprise Products Operating Fox Corp M Williams Cos Inc/The Bayer US Finance II LLC Healti Celgene Corp Healti Dell International LLC / EMC Te Union Pacific Corp Ti Vodafone Group PLC To McDonald's Corp Shire Acquisitions Investments Healti Abbott Laboratories Healti Allergan Funding SCS Healti Southern Co/The CSX Corp Southern Co/The CSX Corp Enbridge Inc E Enbridge Inc E Ensired Finance International NV Enter Communications M Enter Mealti Enter Communications M Enter Mealti Enter Communications M Enter Mealti Enter Mea	onsumer Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	155 123 87 105 139 128 92 99 130	Baa2/BBB+/BBB Baa2/BBB/BBB- Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BBB- Baa3/BBB/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB BBB+ BBB BBB- BBB- BBB+	29 28 25 24 23 22	5% 5% 3% 4% 18%	8% 8% 5% 6%	10% 10% 7% 9%	14% 14% 10%	<15% <15% <15%
Kinder Morgan Inc Amgen Inc Amgen Inc Dow Chemical Co Basic MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Milliams Cos Inc/The Bayer US Finance II LLC Celgene Corp Healt Celgene Corp Dell International LLC / EMC Union Pacific Corp Tr Vodafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Healt Southern Co/The CSX Corp Tr Enbridge Inc Discovery Communications Melatia	Energy th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	123 87 105 139 128 92 99 130	Baa2/BBB/BBB- Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BBB- Baa3/BBB/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB BBB+ BBB- BBB- BBB+	28 25 24 23 22	5% 3% 4% 18%	8% 5% 6%	10% 7% 9%	14% 10%	<15% <15%
Amgen Inc Healt Dow Chemical Co Basic MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Milliams Cos Inc/The Bayer US Finance II LLC Celgene Corp Healt Dell International LLC / EMC Union Pacific Corp Tr Vodafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Healt Southern Co/The CSX Corp Tr Enbridge Inc Discovery Communications Medical Basic B	th & Pharma c Industries Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	87 105 139 128 92 99 130	Baa1/A/BBB Baa2/BBB/NR Baa3/BBB/BBB- Baa3/BBB/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB+ BBB BBB- BBB+	25 24 23 22	3% 4% 18%	5% 6%	7% 9%	10%	<15%
Dow Chemical Co  MPLX LP  Kraft Heinz Foods Co  Enterprise Products Operating Fox Corp  Williams Cos Inc/The  Bayer US Finance II LLC  Celgene Corp  Dell International LLC / EMC  Union Pacific Corp  Vodafone Group PLC  McDonald's Corp  Shire Acquisitions Investments  Anthem Inc  Abbott Laboratories  Allergan Funding SCS  Enel Finance International NV  Southern Co/The  CSX Corp  Tre  CSI CSX Corp  Tre  CDiscovery Communications  Measure  Masser  Measure  Measure	c Industries Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	105 139 128 92 99 130 146	Baa2/BBB/NR Baa3/BBB/BBB- Baa3/BBB/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB BBB- BBB+	24 23 22	4% 18%	6%	9%		
MPLX LP Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Milliams Cos Inc/The Bayer US Finance II LLC Ledgene Corp Dell International LLC / EMC Union Pacific Corp Tr Vodafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications Milliams Co C	Energy onsumer Energy ledia Ent Energy th & Pharma th & Pharma	139 128 92 99 130 146	Baa3/BBB/BBB- Baa3/BBB/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB- BBB- BBB+	23 22	18%			17 /0	N1070
Kraft Heinz Foods Co Enterprise Products Operating Fox Corp Milliams Cos Inc/The Bayer US Finance II LLC Celgene Corp Union Pacific Corp Healti Union Pacific Corp Shire Acquisitions Investments Anthem Inc Abbott Laboratories Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications  Kenterprise Products Occurrence Corp Corp Corp Corp Corp Corp Corp Corp	onsumer Energy ledia Ent Energy th & Pharma th & Pharma	128 92 99 130 146	Baa3/BBB/BBB- Baa1/BBB+/BBB+ Baa2/BBB/-	BBB- BBB+	22		/n%	29%	38%	<15%
Enterprise Products Operating Fox Corp Milliams Cos Inc/The Bayer US Finance II LLC Celgene Corp Healti Dilliams Cos Inc/The Bayer US Finance II LLC Celgene Corp Healti Dilliams Corp Julion Pacific Corp McDonald's Corp Shire Acquisitions Investments Anthem Inc Healti Alborat Laboratories Healti Allergan Funding SCS Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications Milliams Cos Incompage Incompage Inc Discovery Communications Milliams Cos Incompage Incompage Inc Discovery Cos Incompage Incompage Incompage Inc Discovery Cos Incompage I	Energy ledia Ent Energy th & Pharma th & Pharma	92 99 130 146	Baa1/BBB+/BBB+ Baa2/BBB/-	BBB+		24%	34%	38%	49%	<15%
Fox Corp M.  Milliams Cos Inc/The E.  Bayer US Finance II LLC Healti  Celgene Corp Healti  Dell International LLC / EMC Te  Jnion Pacific Corp Tr  Vodafone Group PLC Te  McDonald's Corp  Shire Acquisitions Investments Healti  Abbott Laboratories Healti  Allergan Funding SCS Healti  Enel Finance International NV Couthern Co/The CSX Corp  Enbridge Inc Enclose M.  Discovery Communications M.	ledia Ent Energy th & Pharma th & Pharma	99 130 146	Baa2/BBB/-		21	3%	5%	7%	10%	<15%
Williams Cos Inc/The Bayer US Finance II LLC Celgene Corp Healti Dell International LLC / EMC Union Pacific Corp Tri Vodafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Anthem Inc Healti Allergan Funding SCS Healt Enel Finance International NV Gouthern Co/The CSX Corp Tri Enbridge Inc Discovery Communications Healti Milergan Funding SCS Mi	Energy th & Pharma th & Pharma	130 146			21	4%	6%	8%	11%	<15%
Bayer US Finance II LLC Celgene Corp Healti Dell International LLC / EMC Jnion Pacific Corp Jri /odafone Group PLC McDonald's Corp Shire Acquisitions Investments Anthem Inc Anthem Inc Healti Allergan Funding SCS Healti Enel Finance International NV Southern Co/The CSX Corp Enbridge Inc Discovery Communications Healti Allergan Funding SCS Healti Blood Communications Minimum Color	th & Pharma th & Pharma	146		BBB-	21	21%	30%	33%	44%	<15%
Celgene Corp Health Dell International LLC / EMC Te Union Pacific Corp Tr /odafone Group PLC Te McDonald's Corp Shire Acquisitions Investments Health Anthem Inc Health Abbott Laboratories Health Allergan Funding SCS Health Enel Finance International NV Use Couthern Co/The USCX Corp Enbridge Inc Enbridge Inc Discovery Communications M	th & Pharma		Baa1/BBB/A-	BBB+	20	3%	5%	7%	10%	<15%
Dell International LLC / EMC Union Pacific Corp Union Pacific Corp Industry		104	Baa2/BBB+/-	BBB	20	5%	8%	10%	14%	<15%
Union Pacific Corp Track/odafone Group PLC Televice McDonald's Corp Shire Acquisitions Investments Health Anthem Inc Health Abbott Laboratories Health Allergan Funding SCS Health Enlarge International NV Union Southern Co/The USX Corp Track Enbridge Inc Discovery Communications Medical McGonald Research Color Communications Medical Research Color Communications Medical Research Color Communications Medical Research McGonald Research Color C		180	Baa3/BBB-/BBB-	BBB-	19	24%	34%	38%	49%	15-30%
Vodafone Group PLC         Te           McDonald's Corp         Healt           Shire Acquisitions Investments         Healt           Anthem Inc         Healt           Abbott Laboratories         Healt           Allergan Funding SCS         Healt           Enel Finance International NV         U           Southern Co/The         U           CSX Corp         Tr           Enbridge Inc         E           Discovery Communications         M	ransport	73	Baa1/A-/-	BBB+	19	3%	5%	7%	10%	<15%
McDonald's Corp Shire Acquisitions Investments Healt Anthem Inc Healt Abbott Laboratories Healt Allergan Funding SCS Healt Enel Finance International NV Southern Co/The CSX Corp Trend Inc. Enbridge Inc Enbridge Inc Discovery Communications Mealt	elecoms	134	Baa1/BBB+/BBB+	BBB+	18	3%	5%	7%	10%	<15%
Shire Acquisitions Investments Anthem Inc Abbott Laboratories Healt Allergan Funding SCS Healt Enel Finance International NV Southern Co/The CSX Corp Ti Enbridge Inc Discovery Communications Healt	Retail	77	Baa1/BBB+/BBB	BBB+	18	3%	5%	7%	10%	<15%
Anthem Inc Health Abbott Laboratories Health Allergan Funding SCS Health Enel Finance International NV Southern Co/The CSX Corp Trends Inc Discovery Communications M	th & Pharma	120	Baa2/BBB+/-	BBB	17	5%	8%	10%	14%	<15%
Abbott Laboratories Healti Allergan Funding SCS Healti Enel Finance International NV Southern Co/The CSX Corp Trends Inc. Enbridge Inc Enbridge Inc Moreovery Communications Moreovery	th & Pharma	92	Baa2/A/BBB	BBB	16	5%	8%	10%	14%	<15%
Allergan Funding SCS Healti Enel Finance International NV US Southern Co/The USX Corp Tr Enbridge Inc E Discovery Communications M	th & Pharma	65	Baa1/BBB/WD	BBB	16	5%	8%	10%	14%	<15%
Enel Finance International NV  Southern Co/The  CSX Corp  Enbridge Inc  Discovery Communications  U  U  U  U  U  U  U  U  U  U  U  U  U	th & Pharma	139	Baa3/BBB/BBB-	BBB-	16	24%	34%	38%	49%	<15%
Southern Co/The USX Corp Tr Enbridge Inc E Discovery Communications M	Utilities	185	Baa2/BBB+/A-	BBB+	15	3%	5%	7%	10%	15-30%
CSX Corp Tr Enbridge Inc E Discovery Communications M	Utilities	103	Baa2/BBB+/BBB+	BBB+	14	3%	5%	7%	10%	<15%
Enbridge Inc E Discovery Communications M	ransport	90	Baa1/BBB+/-	BBB+	14	3%	5%	7%	10%	<15%
Discovery Communications Me	Energy	114	Baa2/BBB+/BBB+	BBB+	14	3%	5%	7%	10%	<15%
	ledia Ent	149	Baa3/BBB-/BBB-	BBB-	13	24%	34%	38%	49%	<15%
	ap Goods	82	Baa2/BBB/BBB	BBB	13	5%	8%	10%	14%	<15%
	ransport	95	Baa2/BBB/-	BBB	13	5%	8%	10%	14%	<15%
	th & Pharma	117	Ba1/BBB/BBB-	BBB-	13	24%	34%	38%	49%	<15%
	elecoms	139	Baa3/BBB/BBB	BBB	13	5%	8%	10%	14%	<15%
	Energy	165	Baa3/BBB-/BBB-	BBB-	13	24%	34%	38%	49%	<15%
	th & Pharma	93	A3/BBB+/BBB+	BBB+	13	3%	5%	7%	10%	<15%
	ap Goods	60	Baa1/BBB+/BBB+	BBB+	13	3%	5%	7%	10%	<15%
	Retail	98	Baa1/BBB+/-	BBB+	12	3%	5%	7%	10%	<15%
	elecoms	116	Baa3/BBB-/BBB	BBB-	11	24%	34%	38%	49%	<15%
	Utilities	88	Baa1/BBB+/BBB+	BBB+	11	3%	5%	7%	10%	<15%
0, 1	Utilities	122	Baa3/BBB-/BBB-	BBB-	11	15%	22%	25%	33%	<15%
O, 1	elecoms	123	Baa3/BBB-/BBB	BBB-	11	22%	32%	35%	46%	<15% <15%
	Utilities	123	Baa3/BBB-/BBB-	BBB-	11	8%	12%	14%	20%	<15%
· · · · · · · · · · · · · · · · · · ·		134	Baa2/BBB/-	BBB	11	5%	8%	10%	14%	<15% <15%
		104	DaaziDDDI-	סטט	1.231	97	141	174	234	53
Sum of top 50 Overall BBB Non Fins ex-EM	onsumer				2,341	210	305	367	494	137

Source: J.P. Morgan. As of 14<sup>th</sup> February, 2019. Note: In case of multiple ratings for different bonds for the issuer we display the rating of the largest bond from the largest capital structure of the issuer. The probability of downgrades are calculated on a bond by bond level and aggregated to the issuer level.

### The BBB market has grown rapidly, more so than the BB market

The risk to both High Grade and High Yield bond markets from the rapid growth in BBB rated debt remains a key question for credit investors, and one often cited in HG for those who are cautious on the market. It is an obvious question given the rapid growth in BBB rated debt and the rise in corporate leverage, both of these trends are not been matched in the BB market.

Currently (as of YE18) there is \$2.8tr of BBB rated debt in our JULI index (excluding Emerging Market issuers). This is 51% of the index. Non-Financials are \$2.3tr of this and Financials are \$488bn. 61% of non-Financial debt is now rated BBB, up from 49% in 2011. The rapid growth of the HG market and BBB subset of it in particular has not been matched in High Yield.

The BBB market is currently 4.8x times larger than the BB market, up from 3.6x times 5 years ago and 2.9x times 10 years ago. Therefore, if there is a significant amount of BBB debt downgraded to BB it will have large implications for both HG and HY bond investors.

Exhibit 1: The amount of BBB rated debt has increased by 5.3x since 2007, while BB debt has increased 2.3x. The BBB market is now 4.8 times larger than the BB market






Exhibit 2: The High Grade Non-Financial bond market has grown rapidly over the past few years, driven by BBB rated debt





### The drivers of rating deterioration within High Grade credit include low borrowing costs and significant M&A

Corporate leverage in HG credit markets has risen significantly over the past few years. This has been driven by low borrowing costs for companies, and until the past couple of years, relative weak corporate earnings and EBITDA growth. Companies took advantage of low funding rates to return more cash to shareholders and to undertake transformative M&A deals. They generally locked in a low cost funding, and they borrowed long term in many cases. Therefore, leverage increased, but interest coverage deteriorated less, and rollover risk remains low. Still, the rating agencies reacted to the higher leverage and higher business risk associated with this leverage with rating downgrades. M&A was a key part of the growth in leverage, with M&A funding accounting for 18% of non-Financial bond issuance over the past four years, on average. See our 3Q18 HG Credit Fundamentals report and The M&A Wave: Risk & Reward report for more details.





Exhibit 4: Leverage grew rapidly post the Financial Crisis, as High Grade companies took advantage of low borrowing costs

Source: J.P. Morgan

Exhibit 5: M&A has been a significant driver of higher leverage and lower credit ratings over the past few years. On average leverage increased by 1.6x across 32 large M&A deals since 2015, and has declined only slowly after the deals closed




## Downgrades from HG to HY over the past two years been the lowest two years since 2000

Over the past two years downgrades from HG to HY have averaged just \$17bn/year (0.3% of HG bonds). This is the lowest two year trend in percentage terms since 2000 when our index data begins. Overall, the percentage rate of downgrades from HG to HY was higher almost every year from 2000-2009 than it has been subsequently.


The annual volatility in the data is quite high, understandably. In 2002-2003, there was a spike in downgrades to HY driven by an economic recession and stress in the Telecom and Utilities sectors, in particular. Then, in 2005, downgrades in the Auto sector resulted in \$100bn of debt downgraded in a single year. This is a record that still stands. In 2006-2007, despite strong economic growth, there was still a high rate of downgrades as LBOs of HG companies flourished. In 2008-2009 the Financial crisis led to significant negative rating trends, but these were focused in Financials rather than non-Financials. The downgrades over that period were spread over two years, but combined, they came close to the 2002 and 2005 peaks.

Exhibit 6: Fallen angels from the JULI index have varied significantly year by year



Source: J.P. Morgan

Exhibit 7: Fallen angels as a percent of BBB bonds have been lower post crisis than pre-crisis and especially low the past two years for non-Financials



Source: J.P. Morgan

Post the Financial crisis, there was a sharp decline in downgrades from HG to HY, even as the overall size of the HG market and BBB debt has grown substantially. Some of this is because companies that were able to maintain HG ratings during the sharp recession in 2008-2009 were the stronger ones. Once the economy rebounded, the chances that they would subsequently get in trouble were lower. Also, the low funding costs that corporates enjoyed post-crisis helped reduce the risk of trouble meeting interest payments. The surge in M&A that began in 2014 led to weakening of credit metrics that remains a concern, but post-crisis M&A was mostly strategic in nature, rather than driven by Financial sponsors as was the case pre-crisis. These M&A transactions have, so far, mostly been successful to some extent and have not contributed to more fallen angels. In our analysis of 32 large M&A transactions since 2015, only one of them has subsequently been downgraded to HY. In 2015-2016, the selloff in Energy and Metals prices led to a jump in fallen angels, but the scale of the downgrades then was still well below the pre-crisis trend. There was a change in methodology by Moody's in regards to Energy company ratings in 2016 which contributed to the increase in downgrades. If the rating agencies change their methodologies to be more conservative in the future, and if they do so across their broader coverage universe, there could be a jump in downgrades to HY. We have no reason to expect this, but it remains a risk to the market.

Exhibit 8: Largest fallen angels each year, and the amount of HG index debt impacted

Year	Largest downgrade	Debt downgraded (\$bn)	2nd largest downgrade	Debt downgraded (\$bn)
2000	Xerox Ltd	1.6	Crown Cork & Seal Finance	1.3
2001	Nokia of America Corp	2.9	Delta Air Lines Inc	2.1
2002	MCI Communications Corp	21.1	Qwest Capital Funding Inc	13.7
2003	GPU Inc (FirstEnergy)	4.6	Tenet Healthcare Corp	3
2004	AT&T Corp	8.4	Hess Corp	3.5
2005	Ford Motor Credit Co	45.5	GMAC	30.6
2006	Caesars Ent Operating	4.8	iHeartCommunications	3.6
2007	Centex LLC	6.1	EOP Operating LP	5.4
2008	Lehman Brothers	23.8	Sprint Capital Corp	12.5
2009	CIT Group	12.5	Macy's Retail Holdings	6.4
2010	Intl Lease Finance Corp	10	Anadarko Finance Co	8.9
2011	Embarq Corp	4	RR Donnelley & Sons Co	2.9
2012	ArcelorMittal	12.2	EDP Finance BV	2
2013	Telecom Italia Capital SA	9.6	Arconic Inc (Alcoa Inc)	6.7
2014	Genworth Holdings Inc	3.6	Cleveland-Cliffs(Cliff Natural)	2.9
2015	Transocean Inc	7.5	Teck Resources Ltd	6.9
2016	Freeport-McMoRan Inc	12	Pride International	5.6
2017	Nabors Industries Inc	3.6	Mattel Inc	1.2
2018	Barclays PLC (sub bonds)	5.3	Xerox Corp	4.7
2019	Pacific Gas & Electric	17.0	-	-
Courses	D. Margan			

Source: J.P. Morgan

## Approach 1: The historical downgrade pattern predicts about \$108bn/4.6% of BBB debt could fall to HY each year

To calculate these figures, we start with historical downgrade rates in our JULI index from 2000-2018. Over this period 12.4% of BBB- debt has been downgraded to HY each year on average, 2.7% of BBB flat debt and 1.5% of BBB+ debt has been downgraded as well. Over two years the figures are almost double these levels, but not quite, as debt which falls to HY in one year cannot fall again the next year, so a two year probability is slightly less than 2x the 1yr probability.

Exhibit 9: Percentage of JULI debt downgraded to HY over 1-year depending on rating at the beginning of the year.




Exhibit 11: Historical percentage of HG debt downgraded to HY based on rating bucket each year

1 year	BBB+	BBB-flat	BBB-
Average	2%	3%	12%
Median	0%	1%	10%
Std Dev	3%	3%	10%
Min	0%	0%	2%
Max	11%	13%	45%

Exhibit 10: Percentage of JULI debt downgraded to HY over 2-years depending on rating at the beginning of the first year.




Exhibit 12: Historical percentage of HG debt downgraded to HY based on rating bucket over a two year period

2 year	BBB+	BBB-flat	BBB-
Average	3%	5%	24%
Median	1%	5%	21%
Std Dev	4%	5%	14%
Min	0%	0%	5%
Max	13%	15%	53%

Source: J.P. Morgan, Moody's

Applying these ratios to the current JULI outstanding and ratings distribution results in an estimate of about \$210bn BBB debt downgraded to HY over 2 years and \$305bn over 3 years. This assumes the average downgrade rate occurs, but history shows we rarely see average downgrades. Usually the rate is lower, and then occasionally there is a large spike in downgrades to HY driven by a broader economic slowdown or specific industry challenges. If one uses downgrade probabilities which are one standard deviation worse than the average for each of the BBB rating categories the amount of predicted downgraded debt rises significantly, to \$367bn in 2 years and \$494bn in 3 years.

### Approach 2: Market pricing suggests \$137bn/5.8% of BBB debt is priced in the range of BB debt

Our second approach to estimating fallen angel risk is based on market pricing. A bond's spread level compensates investors for its risks. Therefore, the market implies that credit ratings are "off" when a BBB-rated bond trades at about the same spread level as a generic BB-rated bond with a similar maturity date. This means that market expectations of ratings migration can be inferred from the spread between any BBB bond and a generic BB bond.

In practice, this comparison is not simple. First, both BBB and BB bonds trade in a wide range. Second, there is a significant spread overlap between the two rating buckets, as shown in the Exhibit below. Currently the median BBB bond with 4-6 years to maturity trades around 125bp, while the median BB bond trades at 265bp. About 10% of 4-6yr BBB bonds are trading wider than the mid-point between the two medians (i.e. 195bp), and 7% of BB bonds are trading tighter than that mid-point.

Exhibit 13: BB bonds trade wider than BBB bonds on average, but there is a significant overlap between the distributions





Exhibit 14: Our model of the BBB and BB spread distribution used to assess the market implied rating



Source: J.P. Morgan

Therefore, we believe that the right approach to estimate the market implied ratings is to 1) model the actual distribution of bond spreads<sup>1</sup>, and 2) use that model to determine whether a bond that trades at a given spread level is more likely to be a BBB bond or a BB bond. Note that we restrict ourselves to bonds with 4-6 years to maturity for both BBBs and BBs to avoid bias due to a difference in time to maturity. Note that this approach results in a probability that a BBB bond will fall to BB, based on how much it trades into the BB spread range. We multiply these probabilities at the bond level times the amount of each bond's face value to estimate the implied amount of debt which is priced for a downgrade to High Yield.

Another challenge in using market pricing is that it does not provide the timing for a downgrade from BBB to BB. Ideally, it would be possible to use different maturity date buckets to get some indication of what the market implies in terms of timing for such a downgrade. However, in practice, there are not enough bonds to properly sample these maturity buckets or other subsets.

Our analysis produces one number for the market implied probability of downgrade from BBB to BB. This figure depends on the spread of the specific BBB bond

<sup>&</sup>lt;sup>1</sup> Our model is based on Johnson's S<sub>U</sub>-distribution.

discussed and on the spread distributions of the BBB and BB bonds. There is no precise timing associated with this number. We also prefer to give a range as the outcome for a specific issuer (e.g. 15-30% chance of downgrade) rather than a precise number as our analysis uses some approximations (e.g. in the modeling of the distribution) and to avoid giving a false sense of precision.

Exhibit 15: Market implied probability of downgrade as a function of spread for a BBB bond with 4-6yrs to maturity




Exhibit 16: Par amount of BBB-rated debt with a given market-implied downgrade probability

Probability of downgrade	Amount of BBB Non-Fin debt	% of Non-Fins BBB debt
<25%	\$2,153bn	92%
25%-50%	\$72bn	3%
50%-75%	\$34bn	1%
>75%	\$85bn	4%

Source: J.P. Morgan

We apply this approach in two ways. First, we look at the 50 largest BBB issuers. We use the 5yr point on each issuer's curve<sup>2</sup> as the representative level for that issuer to calculate the market implied downgrade probability. Results are presented in the table on page 3.

Second, we look at the whole BBB market. This time, we use the median spread of all the 4-6yr bonds from each issuer as the representative spread for that issuer. We cannot use our curve model for the broad market as small issuers do not have enough bonds to construct a meaningful curve. We find that \$119bn (5%) of BBB debt has more than 50% chance of being downgraded, according to the market pricing, and that \$75bn (3%) of BBB debt has a larger than 80% chance of being downgraded. Combined, this market-based approach implies that \$137bn/5.8% of BBB debt is priced in the range of BB debt.

<sup>&</sup>lt;sup>2</sup> Issuer curves are based on our model described earlier. It is only applicable to issuers with at least six bonds outstanding.

Eric Beinstein (1-212) 834-4211 eric.beinstein@jpmorgan.com

# Approach 3: Our analysts believe the risk of downgrade to HY for the largest issuers is below that implied by either the historical approach or the market-based approach

For the top 50 BBB rated non-Financials, we asked JPM credit analysts to provide their assessment as to the risk of downgrade to HY, and how it compares to the two quantitative frameworks discussed above. The top 50 BBB issuers represent \$1.2tn in debt which is 53% of the non-Financial ex-EM universe.

We asked them to consider an environment of US GDP growth at around 1.5% for this analysis. This is about the level of potential US growth, and where JPM sees US growth in 4Q19 (and where it is now). It is a level which is not too strong such that it supports across the board strong corporate performance, nor so week that it does the opposite.

Our analysts believe that downgrade risk is lower than that implied by the historical and market pricing approaches for most of the top 50 issuers. For the remaining issuers they believe the quantitative approaches give a probability of downgrade roughly in line with their own views. We did not identify credits where we believe the market is underpricing downgrade risk for this top 50 universe.

In summary, the reasons for the generally optimistic assessment include strong financial flexibility, a commitment to deleveraging and preserving IG ratings by company managements and solid operating performance which is expected to continue. Details by company are below.

### Our forecast is that \$40bn will fall from HG to HY in 2019, \$60bn in 2020.

The historical pattern suggests an approximate rate of \$100bn/year of fallen angels if the average were to prevail, and market pricing suggests, about \$140bn over an unspecified time period, as discussed above. Our analysts, looking at the individual companies, believe the rate will be lower. Our prediction is that the rate of downgrades to HY will remain low for this year and next but will be higher than the past two years which were exceptionally low.

In 2019 \$17bn of Pacific Gas and Electric (PCG) debt was already downgraded from HG and actually defaulted. This is very rare for a bond rated HG as usually bonds are rated HY for some time prior to a default. Our forecast of \$40bn of debt downgraded to HY in 2019 incorporates this amount, so implies a modest amount for the rest of the year. In 2020 we believe the figure will be higher. This is because there is some stress in the Auto sector which may result in downgrades to HY next year. Also, JPM expects US GDP growth to slow throughout 2019 and into 2020. This should result in a higher rate of fallen angels over time.

These forecasts incorporate a view that the trend in fallen angels will remain modest, even as it picks up from current levels. While many companies have taken on more debt and fallen into the BBB and BBB- rating buckets, when we review their prospects individually we do not see stress or reasons for broad based concern. As our analysts discuss below, in most cases we believe companies understand the risks they have taken over the past few years through M&A and a focus on shareholders, and they have/will adjust their strategies as necessary to maintain High Grade ratings.

Of course, there will be negative surprises, and just because companies say they are focused on remaining Investment Grade does not mean that they will succeed. There will be negative events that occur and rating agencies may change their approach or their patience with the pace of deleveraging. Also, we may be headed into a different regulatory environment in the US in a few years, and economic growth may disappoint the trend growth assumption we made in our analysis. We, therefore, continue to expect a steady stream of downgrades, but just not one out of scale with the past two years.

#### A sector by sector review of the top 50 BBB credits

#### Automotive - Jon Rau

Ford Motor Credit Co: With Ford/Ford Credit bonds trading ~30bp wide to our JPM BB index at similar duration, we think the market has arguably priced in the probability of rating agency downgrades to HY. Ford currently sits at Baa3/Negative at Moody's and we think the probability of a downgrade in the next 6 months is increasingly likely amid softer China and Europe markets and the lack of progress around fitness and restructuring initiatives. However, we don't see IG ratings at risk at S&P (BBB/Negative) or Fitch (BBB/Stable) in 2019, though downgrades to BBBat these agencies are possible over the next 6-12 months absent signs of financial and operational improvement. Additionally, we note Ford's firm commitment to preserving IG ratings and believe management could reduce the dividend if internally generated cash flows can no longer support it. At the current juncture, we believe the market implied probability of a downgrade to HY (>90%) is too high as the company's North American operations should continue to generate healthy earnings under the assumption of modest economic growth over the next 2-3 years. In our view, the historically implied downgrade probabilities, even under stressed scenarios (12% probability in 2yrs, 18% probability in 3 yrs), are far too low as they does not consider some of the idiosyncratic challenges the company is currently facing.

General Motors Financial Co: For General Motors/GM Financial, we believe the probability of a downgrade to HY in the next 2 to 3 years is more consistent with the historically-derived estimates (5% in 2 years / 8% in 3 years, and 10% in 2 years / 14% in 3 years under the stressed scenario) under the assumption of continued modest global economic growth. In fact, we see ratings upside potential at GM to high BBB levels in the next few years to the extent that the company executes on targeted restructuring actions intended to generate meaningful free cash flow savings by 2020. We think the 45-60% market-implied downgrade probability is too severe, and more reflective of heightened investor concerns around a near-term recession in the US. We don't believe the market fully appreciates the proactive steps which GM management is taking to improve the company's resilience in a downturn.

#### Chemicals - Jon Rau

**Dow Chemical Co:** We believe the probability of a Dow Chemical downgrade to HY in the next 2 to 3 years is about in-line with both the market-implied (<15%) and historically-derived (4% to 12%) estimates. Dow is one of the world's largest petrochemical producers with advantaged feedstock costs and diverse products/end markets. Management is committed to an investment grade credit profile through the cycle with adj. leverage in the 2.5-3.0x range. While Dow's weaker than expected 4Q18 results and forward guidance highlight the business's sensitivity to volatility in commodity prices, we think the underlying business should remain resilient within the context of a relatively stable macroeconomic environment.

#### Capital Goods - Ginger Chambless

General Electric: We believe downgrade risk to HY for GE is low, in line with the quantitative indicators. While GE's leverage is currently elevated due to weakness in its Power business and challenges in its LTC Insurance book, a number of asset sales to raise cash have been announced or completed to strengthen the balance sheet. We think plans to sell down its remaining BHGE stake and other assets should provide adequate cash resources to meet upcoming maturities, fund restructuring spending, and bolster liquidity.

**Lockheed Martin:** We believe the downgrade risk for Lockheed Martin to HY is very slim, consistent with the quantitative indicators. LMT is a leading defense contractor with significant revenues and contracts with the US Department of Defense. Maintaining a strong balance sheet and investment grade ratings is important for its business. LMT has successfully integrated the Sikorsky helicopter business it acquired a few years ago and gradually reduced leverage back to a very moderate 1.7x at year end 2018.

**Northrop:** We believe the downgrade risk for Northrop to HY is quite low, consistent with the quantitative indicators. NOC is a leading defense contractor with significant revenues and contracts with the US Department of Defense. Maintaining a strong balance sheet and investment grade ratings is important for its business. NOC is in the process of integrating its Orbital ATK acquisition from 2018 and plans to pay down upcoming debt maturities using internally generated cash flow.

**United Technologies:** We believe the downgrade risk for United Technologies to HY is very low, consistent with the quantitative indicators. UTX has increased leverage to approximately 3.6x following its acquisition of Rockwell Collins in 2018, but is focused on repaying debt with its free cash flow over the next few years. UTX is also planning to separate its Climate and Elevator businesses over the next year. UTX has a strong financial profile with significant scale and geographic diversification (\$74bn in revenues), solid EBITDA margins (17%), and strong cash generation.

#### Consumer – Ginger Chambless

**ABInBev:** We believe the downgrade risk for ABInBev to HY is in line with the quantitative metrics, or very low. ABInBev still has elevated leverage (~5x) following its acquisition of SABMiller in 2016, but recently cut its dividend 50% to free up cash for debt repayment. ABInBev otherwise has a very stable financial profile with significant scale and geographic diversification (\$55bn in revenues), high EBITDA margins (40%), and strong cash generation.

BAT Capital Corp: We believe the downgrade risk for British American Tobacco to HY is in line with the quantitative metrics, or low. BATS has elevated leverage (~4x) following its acquisition of Reynolds in 2017, but generates strong cash flows and is prioritizing debt repayment over the next few years. It targets net leverage of 3.3-3.5x by 2019 end with further deleveraging towards its historic 1.5-2.5x target range longer term. BATS is a leading global tobacco company with £25bn in revenue and presence in 200 markets globally. BATS also enjoys high EBITDA margins (42%) and strong cash generation.

**Keurig Dr. Pepper:** We believe downgrade risk for KDP is low, in line with the quantitative factors. KDP leverage is elevated at ∼5.5x following the merger transaction of Dr. Pepper Snapple and Keurig Green Mountain last year. KDP management has expressed a commitment to IG ratings and we think it will reduce leverage fairly quickly via strong cash flows. JAB is KDP's largest shareholder (72%) and JAB has shown willingness to contribute incremental equity to partly finance M&A in order to maintain IG ratings.

**Kraft Heinz:** We believe the downgrade risk for Kraft Heinz to HY is low, which is in line with the market implied level, but lower than what is historically implied by ratings. Although leverage is somewhat elevated at ~4x and underlying business performance has disappointed, KHC management has been crystal clear about financial policy and desire to remain IG. KHC has characterized investment grade ratings as "a line in the sand" and that M&A financing would be structured in a way to stay within IG. KHC's largest investors Berkshire Hathaway (27%) and 3G (22%) have expressed and demonstrated willingness to contribute equity for strategic M&A.

#### Energy - Matthew Anavy

**Enbridge Inc:** We believe that probability of a downgrade to HY is lower than all of these quantitatively derived estimates because Enbridge Inc (ENB) remains one of the largest most diversified Midstream companies in our coverage universe. The company continues to grow its business and access to capital markets and an attractive cost of funding remain very important to the board and management as well as current equity holders. The company recently changed its corporate structure, buying in all of the outstanding units of its affiliate MLPs and eliminating the IDRS from them as well as planning to provide cross guarantees between all of the debt of the parent and the affiliates all with the goal of increasing the credit ratings of ENB.

Energy Transfer Operating: We believe that probability of a downgrade to HY is in line with market pricing but lower than what is historically implied because Energy Transfer Operating (ETP) remains one of the largest most diversified MLPs in our coverage universe and has publically stated they would defend their low BBB ratings if they were at risk of falling to HY. The company, over the years, has taken steps on several occasions to support its IG ratings and we would expect them to do that again in the future if the need should arise. This was also demonstrated by management's patients in simplifying the corporate structure in collapsing legacy ETE and ETP and only moved forward once the combined entity would be IG rated. Finally, the company continues to grow its business and access to capital markets and an attractive cost of funding remain very important to the board and management as well as current equity unit holders.

**Enterprise Products Partners:** We believe that probability of a downgrade to HY is lower than all of these quantitatively derived estimates because Enterprise Products Partners (EPD) remains one of the largest most diversified MLPs in our coverage universe and has publically stated they would defend mid BBB ratings if their ratings were to fall from high BBB level. Additionally, the company continues to grow its business and access to capital markets and an attractive cost of funding remain very important to the board and management as well as current equity unit holders.

Kinder Morgan Inc: We believe that probability of a downgrade to HY is lower than all of these quantitatively derived estimates because Kinder Morgan Inc (KMI) remains one of the largest most diversified Midstream companies in our coverage universe and when the company was at risk for falling to HY the board and management took drastic measures including cutting the distribution in order to retain more cash flow to de-lever the balance sheet in order to preserve IG ratings. We would expect a similar reaction if that were to play out again. Additionally, the company continues to grow its business and access to capital markets and attractive cost of funding remains very important to the companies ability to compete for new business.

**MPLX:** We believe that probability of a downgrade to HY is lower than all of these quantitatively derived estimates because MPLX LP (MPLX) remains one of the largest most diversified refinery MLPs in our coverage universe. The company continues to grow its business and access to capital markets and an attractive cost of funding remain very important to the board and management as well as current equity unit holders. The company currently is evaluating its structure and may become a C-Corp or eliminate the IDRs and remain an MLP in the future all with an eye towards maintaining or improving the companies credit profile.

Sabine Pass Liquefaction: We believe that probability of a downgrade to HY is in line with market pricing but lower than what is historically implied because Sabine Pass Liquefaction LLC remains the largest LNG export terminal in the US. The company has long term service contracts (~20 yrs) that are take or pay in nature that makes the cash flow generation profile of SPLLLC similar to that of a utility. The company retains very little commodity price risk in its business but does have significant debt maturities that will need to be refinanced in a cost efficient manner and maintaining IG is a key part of management's strategy.

William Cos: We believe that probability of a downgrade to HY is lower than all of these quantitatively derived estimates because William Cos (WMB) remains one of the largest most diversified Midstream companies in our coverage universe. The company continues to grow its business and access to capital markets and an attractive cost of funding remain very important to the board and management as well as current equity unit holders. The company recently changed its corporate structure, collapsing its GP and LP into the GP which was also a C-Corp and eliminated its IDRs all with an eye towards maintaining or improving the companies credit profile. We see WMB as migrating to the mid BBB rating category over the coming 12-18 months under nearly all economic scenarios.

#### Healthcare/Pharmaceuticals - Brett Gibson

**AbbVie:** We see ABBV's risk of downgrade to HY as relatively low within a 2/3 year time period, about in line with the metrics listed in the table. While a substantial component of its profits come from a single product (Humira represents 61% of sales and a slightly higher percentage of EBITDA) which will face generic competition in 2023 in the US, the company has agreements in place with nearly all potential generic entrants to limit a launch until a period between Jan 2023 and Nov 2023. This period of time prior to generic launch will give the company the time and ability to use its current very strong cash flow to prepare for that event and bring new products to market. Wildcards include losing substantial US Humira market share to the single generic company which is challenging the Humira patent in court (and is

targeting going to market prior to 2023) or aggressive debt financed M&A that is inconsistent with recent company comments.

Allergan: We would characterize the risk of AGN going HY over the next 2/3 years as similar to the quantitative metrics (14%/19% base case, 19%/25% stress case) despite some of the risks inherent in the name. Notable risks include the company expecting to lose ~\$1bn of EBITDA contribution from Restasis once the FDA approves a generic version of the drug and the stock having dramatically underperformed peers, drawing some level of activist interest. While these risks mean that a downgrade to HY is not out of the question, in our view the company's entrenched Botox franchise and historical commitment act as a buffer. We largely view ratings under the company's control and it has shown a strong commitment to IG ratings that would likely cause it to pull levers to stay investment grade.

Amgen Inc: We view the risk of HY for AMGN as very low given its very strong FCF, relatively diversified profile, and significant balance sheet cash (\$29.3bn). The company is likely to be active in M&A, but we expect that M&A will largely center around pipeline assets that from a size perspective can be funded out of cash flows. In our view, any possible downgrade to HY would likely have to include multiple succession credit negative events— a mega merger which depletes its large cash balance and is aggressively debt financed, followed by a dramatic underperformance of the target relative to company expectations.

**Anthem Inc:** We view the likelihood of a downgrade to HY as low (in line to lower than the quantitative metrics) given the company's large footprint and strong Blue presence which tends to make its medical membership sticky. One wildcard is the potential for a Single Payer/Medicare-for-all system gaining more traction as we enter the 2020 election, but we believe that any potential change would be gradual and that many of the large Managed Care players would have a say in how the system evolves.

**Becton Dickinson:** We see a downgrade to full HY as lower than the quantitatively derived rating metrics, though we note that spreads imply a low probability which is more consistent with our view. BDX already carries one Ba1 rating, a result of its 2017 acquisition of BCR. But after strong operating performance and steady deleveraging, our base case is for the company to regain full investment grade this year. A downgrade to full HY would require significant operating setbacks that seem unlikely in our opinion, considering the stable nature of many of BDX's products.

**Cigna Corp:** We view the chance of CI going HY in the next 2/3 years as extremely low, lower than the already low metrics in the table. CI benefits from a strong market position and strong free cash flow relative to debt which should allow it to delever quickly and in accordance with its plan. CI's recent acquisition of ESRX introduces risk from its large transitioning client, but the company has fully prepared for this eventuality. One wildcard is the litigation with ANTM related to the legacy ESRX contract where ANTM is suing for a significant amount based on its view of contract breaches.

CVS Health Corp: We would characterize the chance of a CVS downgrade to HY as low, consistent or slightly lower than the quantitatively derived metrics. After increasing leverage materially (to ~4.6x) to fund the AET transaction, CVS has embarked on an ambitious plan to change the healthcare system, but has also committed to rapidly bringing down debt levels and consistently shown its commitment to Investment Grade ratings. A downgrade to HY would require a significant model change in the healthcare/drug supply chain, but we note that changes tend to occur slowly in Healthcare and CVS possesses a number of levers that could assist keeping IG ratings in a challenging environment.

#### Healthcare/ Pharmaceuticals - Danielle Ward

AstraZeneca: We would agree that the risk of AZN being downgraded to HY is very low. The company has transitioned from being rated single A by all three agencies in 2017 to its current BBB+ ratings at S&P/Fitch (remains A3 at Moody's, on Negative outlook), following a number of acquisitions while maintaining a generous dividend policy. AZN has said that the group remains committed to a strong investment grade rating, and now has a healthier organic growth outlook than in past years, having rebuilt its product pipeline, while maintaining flexibility to reduce shareholder payouts (and prioritise cash flow for net debt management) should the need arise to protect ratings. We think large-scale M&A is a relatively low likelihood for AZN given its current pipeline, but a more aggressive stance would be the main risk to watch out for when considering prospects for multi-notch downgrades.

#### Healthcare/Pharmaceuticals – Jemma Permalloo

Bayer: We believe that the probability of a downgrade to HY is very low and about equal to these quantitatively derived estimates. Bayer was downgraded by two notches to 'BBB' by S&P in June 2018 following its \$63bn acquisition of Monsanto and its increased leverage. Bayer's senior unsecured debt was also downgraded by Moody's, from 'A3' to 'Baa1'. While Bayer's rating is weakly positioned in the short-term, the scale of the acquisition has helped towards Bayer solidifying and improving its business profile. We also note that Bayer still has more than 9,000 outstanding cases in regard to the glyphosate litigation but in our view, its liquidity position could sufficiently meet any additional fines or damages. We also take comfort in Bayer's ambitious target of reaching more than 30% EBITDA margin, further debt reduction to €26-28bn and FCF generation by 2022. Bayer could face downward pressure on its ratings should it face delays on its deleveraging path or severe integration problems with Monsanto.

#### Media/Entertainment – Brian Turner

Charter Communications: We believe the probability of a downgrade to HY for the secured bonds in the Charter capital structure is lower than the quantitatively derived estimates. With over \$53bn of secured debt outstanding, we cannot envision a scenario where Charter intentionally allows the secured bonds to drop to HY, particularly given the capital structure implications and loss of access to long-dated, low cost financing in the IG market. Furthermore, Charter remains committed to keeping leverage within the range of maintaining IG ratings and given the inherent defensiveness of the cable business we don't foresee a downgrade in the near future.

#### Retail - Ginger Chambless

**Lowes Cos:** We believe downgrade risk to HY is in line with quantitative indicators for Lowes. LOW is the second largest home improvement retailer in the US with \$71bn of revenues. Although LOW recently raised its leverage target to 2.75x in order to return more cash to shareholders, we view the absolute level of leverage as moderate and manageable given the cyclicality (housing exposure). LOW also has significant real estate ownership which we view as a credit positive.

**McDonalds:** We believe downgrade risk for MCD to HY is very low, which is in line with the quantitative factors. MCD's largely franchised business model is very stable. MCD has global operations, high EBITDA margins, and strong cash flows. MCD adopted a more aggressive financial policy in late 2015 and took downgrades to BBB+ (from single A) where it has added incremental leverage to return more cash to shareholders. MCD has raised its dividend 36% since 2015 and repurchased \$21bn of stock. We view the elevated levels of share repurchases as an area of flexibility MCD could pull back on if needed to defend IG ratings.

#### Technology – Brian Turner

**Dell:** Similar to our views on Charter, we believe the probability of a downgrade to HY for Dell is lower than the quantitatively derived estimate. Dell currently has over \$30bn of secured debt with the majority (\$20bn) having punitive coupon steps, an outcome we believe management is keen to avoid. Dell continues to express their interest in becoming a full IG company (a goal set at the outset of the EMC deal) despite a lack of material progress toward achieving that goal. While we do believe that Dell is susceptible to an economic slowdown and a weaker-than expected IT environment, we believe management is committed to keeping IG ratings on the secured bonds.

#### Telecoms - Brian Turner

American Tower Corp: We believe the probability of a downgrade to HY is lower than the quantitatively derived estimate. We find the operating profiles of tower operators as defensive in nature, supported by the development of network infrastructure and increased demand from telecom operators to improve their networks and build out 5G. While leverage remains at the high end of management's target of 3-5x, we believe the fundamental credit profile of AMT remains sound and believe AMT management is committed to IG ratings given their public comments. We continue to expect a favorable operating environment for tower operators over the next few years.

AT&T: Despite being the most indebted non-financial, we believe the probability of a downgrade to HY for AT&T is lower than the quantitatively derived estimates for several reasons. First and foremost, we believe the defensive nature of the U.S. telecom business provides the company with a very stable stream of revenues and cash flows. Second, we believe AT&T management has set achievable de-leveraging targets. Management is committed to taking out \$15-20bn of debt in 2019 through a combination of pay downs, tenders, open market transactions and asset sales. Lastly, we believe if management is able to execute on plans to stabilize the entertainment business (DTV) and drive growth from the Time Warner assets, investor concern should dissipate on the achievability of management's de-leveraging goals.

Crown Castle International: We believe the probability of a downgrade to HY for CCI is lower than the quantitatively derived estimates given the fundamental position of cell tower infrastructure companies. Following the acquisition of Lightower in 2017, CCI leverage spiked significantly. Management quickly de-levered towards their target leverage of ~5x, and it's our view that they remain committed to investment grade credit ratings, as illustrated by their public comments and willingness to use equity to support any additional M&A.

Telefonica: We believe the probability of a downgrade to HY for TELEFO is lower than the quantitatively derived estimates. Management has taken a credit-friendly approach to capital allocation and has reaffirmed commitments to "solid investment grade" credit ratings on earnings calls. Net debt has decreased seven quarters in a row and management expects €1.4bn of additional debt reduction next quarter as it uses asset sale proceeds from sales of its stakes in Central America. The company continues to discuss potential further asset sales, though without pointing to specific assets. Furthermore, recent results have been encouraging, though we do believe that rising competition in Spain will remain a pressure point in addition to continued mixed emerging market results.

Verizon Communications Inc: We believe the probability of a downgrade to HY is lower than the quantitatively derived estimates. Verizon management has differentiated themselves from peers on strategy, favoring a focus on network leadership and balance sheet strengthening over debt-financed M&A. Management has reiterated on multiple occasions that the company is on the trajectory to return to pre-Vodafone credit ratings (single-A), with total net debt down \$4.7bn in 2018. Furthermore, we believe the defensive nature of the telecom business along with Verizon's position as the top carrier from both a performance and financial perspective will support credit ratings under most economic scenarios.

**Vodafone Group:** Although leverage levels remain elevated, we believe the probability of a downgrade to HY is roughly in-line with the quantitatively derived estimates. Vodafone's inherent defensive nature as a telecom operator provides stability; the risk of levering M&A – significant enough to make HY ratings a real possibility – is less than 10% in our view.

#### Transportation – Mark Streeter

CSX Corp: We believe the probability of a downgrade for CSX is lower due to its strong operating momentum and current leverage level. Unlike UNP and NSC, CSX has not made a public commitment to BBB+ ratings. We still have no reason to believe the company will fall below BBB flat (and for 2019 high BBB ratings will likely stick, we're more worried about 2020). Strong operating margin momentum (we expect at least \$250mm in cash from operations y/y, note adjusted free cash flow increased 88% or \$1.5bn y/y) and very manageable planned capex (-\$100mm for 2019, 2018 capex declined \$300mm) should keep the leverage ratio right on the cusp of the BBB+/BBB cliff (2.7-2.8x leverage range is our best guess, we think a ratio slightly higher, say just under 3x, would trigger one notch downgrades).

**FedEx Corp:** FDX is a solid BBB transportation credit, in our opinion. The continued headlines around Amazon entering the last mile distribution space have put pressure on the stock. However, we note that the threat, for now, to FedEx's top line is minimized by the fact that AMZN only accounts for 3% of FDX volumes. The TNT integration was set back by the lingering aftermath of the 2017 cyberattack. We believe that the TNT acquisition will be strategically accretive to FDX over time as it importantly bolsters the company's European network, although it will take time to sort out the technological headwinds. What we liked most about the TNT transaction is that FDX showed discipline in not chasing TNT the first time this company was up for sale (UPS had agreed to pay ~\$6.7bn in 2012 before regulators blocked the deal, and about three years later FDX bought the company for \$4.8bn or almost 30% less). Almost two decades ago, when we began covering FDX (1999 to be exact), the concern was that email and the internet would slowly (or quickly) drive down FDX volumes. Fast forward to 2018, and the internet (and e-commerce specifically) has proven to be a windfall. FDX's Ground business (which handles much of the company's retail e-commerce shipping and didn't materially exist back then, of course) continues to increase volumes at a pace materially higher than core GDP growth. Ground also continues to expand margins and now boasts the highest margin among FDX's three major business lines. What holds us back from being more bullish on this story is our expectation for management to continue to prioritize shareholder returns and growth capex over debt repayment and deleveraging. While we do believe ratings can migrate higher to high BBB, we think upside is capped by management's focus on share performance. We don't envision a scenario where FedEx organically falls to even low BBB-. Any downgrades would be self-inflicted, more likely from not prudently curtailing share repurchases if the economy (and therefore FDX operating cash flow) slows materially.

Union Pacific Corp: We believe the probability of a downgrade for UNP is lower due to their established commitment to high BBB ratings. While UNP did suffer one-notch downgrades at S&P (from A to A-) and at Moody's (from A3 to Baa1), UNP management also committed to maintaining ratings at or above BBB+. The company is also in the process of implementing Precision Scheduled Railroading ("PSR") network operating system which should continue improve the company's operating performance as it has for CNRCN, CP, and CSX. UNP took a major step in its PSR implementation journey by hiring Hunter Harrison disciple Jim Vena as its COO (Hunter of course is the deceased executive who implemented PSR successfully at CN and CP and got the PSR ball rolling at CSX). Mr. Vena has already dropped a "few hundred" locomotives in his first 10 days on the job, which as noted by our equity partners is the first concrete example of his expertise in PSR. As noted in 3Q18, current leverage is 2.3x at YE looking back but the new target is up to 2.7x (which should leave ratings at BBB+ worst case, and likely keep S&P at A- if PSR implementation doesn't cause any major disruptions).

#### Utilities - Claire Barbour

**Duke Energy:** We believe there is a very low risk of DUK being downgraded to HY over the next few years. In our opinion, the probability is even lower than the estimates derived in the corresponding table. DUK's business risk profile is supported by its size and overall diversification, as it is one of the largest utilities in our coverage universe, with business operations spread across various above average regulatory jurisdictions. Additionally, DUK's derives primarily all its revenues from its regulated utility subsidiaries, further supporting its credit quality and underscoring the low-risk nature of the broader industry.

Broadly speaking, the standard cost-of-service utility business model provides significant insulation from credit quality deterioration warranting rating downgrades below Investment Grade, given the considerable oversight and authority granted to regulatory commissions governing the industry. Regulated utilities typically operate under predetermined rate plans and mandatory capital structures, as established by each respective regulatory jurisdiction. Ultimately, this provides greater certainty into future cash flows and earnings. Finally, regulators also have the ability to implement incremental measures necessary to support utility credit quality, further protecting the industry from the likelihood of rating downgrades over unexpected adverse events.

**Exelon Corp:** We believe the probability of EXC being downgraded to HY over the new few years is lower than the estimates derived. We acknowledge EXC is one of the few remaining HG utilities with an integrated business model with unregulated operations (ExGen) accounting for approximately 35% of revenues. However, we note ExGen's cash flows are currently being utilized to fund capex at both regulated and unregulated businesses, deleveraging measures, and partially cover the external dividend. Ultimately, we believe this helps to minimize the EXC's need to access the capital markets, which we view favorably.

In the event, EXC were to separate itself from its competitive genco, we believe there is a significantly high likelihood of being ExGen being downgraded to HY. Historically, other integrated companies, such as PPL, EIX and AEE, have also exited their unregulated gencos, which ultimately resulted in ratings upgrades for the holding company. We note management continues to reiterate its commitment to ExGen. However, in our opinion, sustained weakness in power market fundamentals further pressures the industry and will accelerate questions to management teams around strategic viability in the space.

**FirstEnergy Corp:** We believe the probability of FE being downgraded to HY over the new few years is lower than the estimates derived. While we recognize FE is one of the lowest rated utilities within our coverage universe, we actually view the company as an improving credit story. FE has taken extraordinary measures over the last few to exit its volatile unregulated businesses, in credit neutral manner. FE's unregulated Genco (FirstEnergy Solutions) was one the primary reasons driving its weaker credit quality and low ratings, as compared to the broader utility sector. We consider FE a fully regulated utility, underlying portfolio of diversified regulated subsidiaries operating in favorable regulatory jurisdictions. We anticipate a Fitch ratings upgrade in the near-term, underscoring the company's recent improving qualifications.

Broadly speaking, the standard cost-of-service utility business model provides significant insulation from credit quality deterioration warranting rating downgrades below Investment Grade, given the considerable oversight and authority granted to regulatory commissions governing the industry.

Regulated utilities typically operate under predetermined rate plans and mandatory capital structures, as established by each respective regulatory jurisdiction. Ultimately, this provides greater certainty into future cash flows and earnings. Finally, regulators also have the ability to implement incremental measures necessary to support utility credit quality, further protecting the industry from the likelihood of rating downgrades over unexpected adverse events.

**Southern Company:** We believe the probability of SO being downgraded to HY over the new few years is lower than the estimates derived. Southern Company has recently confronted cost overruns and extended delays to its in-service date for its capital intensive nuclear construction project in Georgia. The state remains fully committed and supportive of the company and its respective nuclear project, a key consideration, in our opinion. Additionally, the company took significant steps to support credit quality, following negative impacts from tax reforms, which lead to incremental ratings pressure.

Broadly speaking, the standard cost-of-service utility business model provides significant insulation from credit quality deterioration warranting rating downgrades below Investment Grade, given the considerable oversight and authority granted to regulatory commissions governing the industry. Regulated utilities typically operate under predetermined rate plans and mandatory capital structures, as established by each respective regulatory jurisdiction. Ultimately, this provides greater certainty into future cash flows and earnings. Finally, regulators also have the ability to implement incremental measures necessary to support utility credit quality, further protecting the industry from the likelihood of rating downgrades over unexpected adverse events.

## Other credits not in the top 50 BBB issuer list with significant fallen angel risk

#### Consumer - Ginger Chambless

Campbell Soup: We think downgrade risk for Campbell is modestly higher than the quantitative factors indicate, based on our view that underlying business trends could continue to be softer than needed to materially improve the leverage profile. CPB recently named a new CEO (Mark Klouse, former CEO of Pinnacle) and reached an agreement with activist investors following a six month proxy fight. CPB is in the process of auctioning its international cookie business to raise cash for debt reduction. Press reports suggest a sale could happen this spring for proceeds of \$3bn. CPB has expressed a desire to maintain IG ratings and is targeting net leverage of 3x by fiscal 2021 vs 5.1x net currently.

Conagra Brands Inc: We believe CAG downgrade risk is towards the higher end of what the quantitative indicators suggest in the 30-40% area. While we believe CAG is committed to an IG profile, its leverage is quite elevated (5.3x) following the Pinnacle acquisition and the performance of that business was much worse than expected once it was acquired. In December, CAG reported very disappointing results with Pinnacle experiencing high single digit sales declines. It will likely take CAG longer than expected to de-lever and we think the company may need to sell assets to de-lever. Conagra is targeting gross leverage of 3.5x by the end of fiscal 2021, and we think if the company is not able to stabilize Pinnacle and reduce leverage, downward rating pressure could build.

**Newell Brands:** We believe downgrade risk for NWL to HY is between its rating implied levels and spread implied levels, in the 45-55% area. NWL has made notable progress on its transformation plan announced in March 2018 to sell non-core businesses, and applied \$3.5bn of proceeds to pay down debt. It reached its target gross leverage of 3.5x at 2018 end and plans to further reduce debt. NWL has a long standing commitment to IG ratings demonstrated by coupon steps in its bonds and historical dividend cut. However, underlying results remain weak and core sales are expected to decline over the next year. This could put pressure on credit metrics unless a greater than expected portion of asset sale proceeds are used to reduce debt.

#### Healthcare/Pharmaceuticals – Brett Gibson

Mylan: We see the risk of the company being downgraded to HY over the next 2/3 years as in excess of the rating-implied probabilities (~20-40%), but see spreads currently pricing in more than is warranted (~60-75%). The company is currently in the midst of a broad strategic review (initiated on Aug 8) with "everything on the table". Notably in response to recent questions on if it is committed to balance sheet strength through the review, the company stated it sees the balance sheet as important, but is "not tying its hands" as it looks at all opportunities. Further, the company is currently planning to repay debt to satisfy its ratings commitment, but the CFO stated that if something comes out of the committee's decision, then "maybe there's an adjustment". That's the uncertain zone that MYL credit currently finds itself. While operations have been up and down and MYL, similar to peers, faces a number of challenges in the generics market, we believe it could maintain IG ratings if it wanted to and took appropriate action, but with a significantly underperforming stock and historically low multiple, that simply cannot be relied on.

North America Credit Research 21 February 2019

Eric Beinstein (1-212) 834-4211 eric.beinstein@jpmorgan.com J.P.Morgan

MYL has not given a timetable on announcing a strategic review decision, but has said it plans to give an "update on timing" on its Feb 26 earnings call.

Analyst Certification: All authors named within this report are research analysts unless otherwise specified. The research analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an "AC" on the cover or within the document individually certifies, with respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers; and (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. For all Koreabased research analysts listed on the front cover, they also certify, as per KOFIA requirements, that their analysis was made in good faith and that the views reflect their own opinion, without undue influence or intervention.

#### **Important Disclosures**

Company-Specific Disclosures: Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan—covered companies by visiting <a href="https://www.jpmm.com/research/disclosures">https://www.jpmm.com/research/disclosures</a>, calling 1-800-477-0406, or e-mailing <a href="research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a> with your request. J.P. Morgan's Strategy, Technical, and Quantitative Research teams may screen companies not covered by J.P. Morgan. For important disclosures for these companies, please call 1-800-477-0406 or e-mail <a href="research.disclosure.inquiries@jpmorgan.com">research.disclosure.inquiries@jpmorgan.com</a>.

#### Explanation of Credit Research Valuation Methodology, Ratings and Risk to Ratings:

J.P. Morgan uses a bond-level rating system that incorporates valuations (relative value) and our fundamental view on the security. Our fundamental credit view of an issuer is based on the company's underlying credit trends, overall creditworthiness and our opinion on whether the issuer will be able to service its debt obligations when they become due and payable. We analyze, among other things, the company's cash flow capacity and trends and standard credit ratios, such as gross and net leverage, interest coverage and liquidity ratios. We also analyze profitability, capitalization and asset quality, among other variables, when assessing financials. Analysts also rate the issuer, based on the rating of the benchmark or representative security. Unless we specify a different recommendation for the company's individual securities, an issuer recommendation applies to all of the bonds at the same level of the issuer's capital structure. This report also sets out within it the material underlying assumptions used.

We use the following ratings for bonds (issues) and issuers: Overweight (over the next three months, the recommended risk position is expected to outperform the relevant index, sector, or benchmark); Neutral (over the next three months, the recommended risk position is expected to perform in line with the relevant index, sector, or benchmark); and Underweight (over the next three months, the recommended risk position is expected to underperform the relevant index, sector, or benchmark). J.P. Morgan Emerging Markets Sovereign Research uses Marketweight, which is equivalent to Neutral. NR is Not Rated. In this case, J.P. Morgan has removed the rating for this particular security or issuer because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating no longer should be relied upon. An NR designation is not a recommendation or a rating. NC is Not Covered. An NC designation is not a rating or a recommendation.

For CDS, we use the following rating system: Long Risk (over the next three months, the credit return on the recommended position is expected to exceed the relevant index, sector or benchmark); Neutral (over the next three months, the credit return on the recommended position is expected to match the relevant index, sector or benchmark); and Short Risk (over the next three months, the credit return on the recommended position is expected to underperform the relevant index, sector or benchmark).

#### J.P. Morgan Credit Research Ratings Distribution, as of January 02, 2019

	Overweight	Neutral	Underweight
Global Credit Research Universe	25%	58%	17%
IB clients*	65%	64%	57%

<sup>\*</sup>Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

**Analysts' Compensation:** The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

#### **Other Disclosures**

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

The Credit Research Rating Distribution is at the issuer level. Issuers with an NR or an NC designations are not included in the table above. This information is current as of the end of the most recent calendar quarter.

Any data discrepancies in this report could be the result of different calculations and/or adjustments.

Options and Futures related research: If the information contained herein regards options or futures related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit <a href="https://www.theocc.com/components/docs/riskstoc.pdf">https://www.theocc.com/components/docs/riskstoc.pdf</a> for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or <a href="http://www.finra.org/sites/default/files/Security\_Futures\_Risk\_Disclosure\_Statement\_2018.pdf">http://www.finra.org/sites/default/files/Security\_Futures\_Risk\_Disclosure\_Statement\_2018.pdf</a> for a copy of the Security Futures Risk Disclosure Statement

**Private Bank Clients:** Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries ("J.P. Morgan Private Bank"), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including but not limited to the J.P. Morgan corporate and investment bank and its research division.

#### **Legal Entities Disclosures**

U.S.: JPMS is a member of NYSE, FINRA, SIPC and the NFA. JPMorgan Chase Bank, N.A. is a member of FDIC. Canada: J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Investment Industry Regulatory Organization of Canada and the Ontario Securities Commission and is the participating member on Canadian exchanges. U.K.: JPMorgan Chase N.A., London Branch, is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and to limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from J.P. Morgan on request. J.P. Morgan Securities plc (JPMS plc) is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Registered in England & Wales No. 2711006. Registered Office 25 Bank Street, London, E14 5JP. Germany: This material is distributed in Germany by J.P. Morgan Securities plc, Frankfurt Branch which is regulated by the Bundesanstalt für Finanzdienstleistungsaufsich and also by J.P. Morgan AG (JPM AG) which is a member of the Frankfurt stock exchange and is regulated by the Federal Financial Supervisory Authority (BaFin), JPM AG is a company incorporated in the Federal Republic of Germany with registered office at Taunustor 1, 60310 Frankfurt am Main, the Federal Republic of Germany. South Africa: J.P. Morgan Equities South Africa Proprietary Limited is a member of the Johannesburg Securities Exchange and is regulated by the Financial Services Board. Hong Kong: J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong and/or J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. Korea: This material is issued and distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch, which is a member of the Korea Exchange(KRX) and is regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). Australia: J.P. Morgan Securities Australia Limited (JPMSAL) (ABN 61 003 245 234/AFS Licence No. 238066) is regulated by ASIC and is a Market, Clearing and Settlement Participant of ASX Limited and CHI-X. Taiwan: J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. India: J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai - 400098, is registered with Securities and Exchange Board of India (SEBI) as a 'Research Analyst' having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited (SEBI Registration Number - INB 230675231/INF 230675231/INE 230675231), the Bombay Stock Exchange Limited (SEBI Registration Number - INB 010675237/INF 010675237) and as a Merchant Banker (SEBI Registration Number -MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: www.jpmipl.com. For non local research reports, this material is not distributed in India by J.P. Morgan India Private Limited. Thailand: This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500. Indonesia: PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is regulated by the OJK a.k.a. BAPEPAM LK. Philippines: J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. Brazil: Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Mexico: J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is a member of the Mexican Stock Exchange and authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. Singapore: This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMSS) [MCI (P) 099/04/2018 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) [MCI (P) 046/09/2018], both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of "accredited investors," "expert investors" or "institutional investors," as defined under Section 4A of the SFA. Recipients of this document are to contact JPMSS or JPMCB Singapore in respect of any matters arising from, or in connection with, the document. Japan: JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan. Malaysia: This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission in Malaysia. Pakistan: J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan. Saudi Arabia: J.P. Morgan Saudi Arabia Ltd. is authorized by the Capital Market Authority of the Kingdom of Saudi Arabia (CMA) to carry out dealing as an agent, arranging, advising and custody, with respect to securities business under licence number 35-07079 and its registered address is at 8th Floor, Al-Faisaliyah Tower, King Fahad Road, P.O. Box 51907, Riyadh 11553, Kingdom of Saudi Arabia. Dubai: JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - Building 3, Level 7, PO Box 506551, Dubai, UAE. Russia: CB J.P. Morgan Bank International LLC is regulated by the Central Bank of Russia. Argentina: JPMorgan Chase Bank Sucursal Buenos Aires is regulated by Banco Central de la República Argentina ("BCRA"- Central Bank of Argentina) and Comisión Nacional de Valores ("CNV"-Argentinian Securities Commission")

#### **Country and Region Specific Disclosures**

U.K. and European Economic Area (EEA): Unless specified to the contrary, issued and approved for distribution in the U.K. and the EEA by JPMS plc. Investment research issued by JPMS plc has been prepared in accordance with JPMS plc's policies for managing conflicts of interest arising as a result of publication and distribution of investment research. Many European regulators require a firm to establish, implement and maintain such a policy. Further

information about J.P. Morgan's conflict of interest policy and a description of the effective internal organisations and administrative arrangements set up for the prevention and avoidance of conflicts of interest is set out at the following link https://www.jpmorgan.com/jpmpdf/1320742677360.pdf. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only available to relevant persons and will be engaged in only with relevant persons. In other EEA countries, the report has been issued to persons regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party or outside Australia without the prior written consent of JPMSAL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001, J.P. Morgan's research coverage universe spans listed securities across the ASX All Ordinaries index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all GIC sectors, as well as across a range of market capitalisation sizes. Germany: This material is distributed in Germany by J.P. Morgan Securities plc, Frankfurt Branch which is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. Hong Kong: The 1% ownership disclosure as of the previous month end satisfies the requirements under Paragraph 16.5(a) of the Hong Kong Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission. (For research published within the first ten days of the month, the disclosure may be based on the month end data from two months prior.) J.P. Morgan Broking (Hong Kong) Limited is the liquidity provider/market maker for derivative warrants, callable bull bear contracts and stock options listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: http://www.hkex.com.hk. Korea: This report may have been edited or contributed to from time to time by affiliates of J.P. Morgan Securities (Far East) Limited, Seoul Branch. Singapore: As at the date of this report, JPMSS is a designated market maker for certain structured warrants listed on the Singapore Exchange where the underlying securities may be the securities discussed in this report. Arising from its role as designated market maker for such structured warrants, JPMSS may conduct hedging activities in respect of such underlying securities and hold or have an interest in such underlying securities as a result. The updated list of structured warrants for which JPMSS acts as designated market maker may be found on the website of the Singapore Exchange Limited: http://www.sgx.com. In addition, JPMSS and/or its affiliates may also have an interest or holding in any of the securities discussed in this report - please see the Important Disclosures section above. For securities where the holding is 1% or greater, the holding may be found in the Important Disclosures section above. For all other securities mentioned in this report, JPMSS and/or its affiliates may have a holding of less than 1% in such securities and may trade them in ways different from those discussed in this report. Employees of JPMSS and/or its affiliates not involved in the preparation of this report may have investments in the securities (or derivatives of such securities) mentioned in this report and may trade them in ways different from those discussed in this report. Taiwan: Research relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material which may give rise to conflicts of interests, unless otherwise disclosed in the "Important Disclosures" in this material. India: For private circulation only, not for sale. Pakistan: For private circulation only, not for sale. New Zealand: This material is issued and distributed by JPMSAL in New Zealand only to persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually invest money. JPMSAL does not issue or distribute this material to members of "the public" as determined in accordance with section 3 of the Securities Act 1978. The recipient of this material must not distribute it to any third party or outside New Zealand without the prior written consent of JPMSAL. Canada: This report is distributed in Canada by or on behalf of J.P.Morgan Securities Canada Inc. The information contained herein is not, and under no circumstances is to be construed as an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient.

General: Additional information is available upon request. Information has been obtained from sources believed to be reliable but JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) do not warrant its completeness or accuracy except with respect to any disclosures relative to JPMS and/or its affiliates and the analyst's involvement with the issuer that is the subject of the research. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. JPMS distributes in the U.S. research published by non-U.S. affiliates and accepts responsibility for its contents. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Clients should contact analysts and execute transactions through a J.P. Morgan subsidiary or affiliate in their home jurisdiction unless governing law permits otherwise.

"Other Disclosures" last revised January 19, 2019.

Copyright 2019 JPMorgan Chase & Co. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.